Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells

Infection and Immunity

Volumn 81, Issue 8, 2013, Pages 2678-2685

  Ehrlenbach, Silvia ^a   Rosales, Alejandra ^a   Posch, Wilfried ^a   Wilflingseder, Doris ^a   Hermann, Martin ^a   Brockmeyer, Jens ^b   Karch, Helge ^b   Satchell, Simon C ^c   Würzner, Reinhard ^a   Orth Höller, Dorothea ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; VEROTOXIN 2;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELL SURFACE; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; GLOMERULUS; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD59; CELL LINE; ENDOTHELIAL CELLS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTIONS; FLOW CYTOMETRY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY GLOMERULUS; KIDNEY TUBULES, PROXIMAL; MICROSCOPY, CONFOCAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SHIGA TOXIN 2;

EID: 84880648308     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01079-12     Document Type: Article

References (47)

1. Karch H, Tarr PI, Bielaszewska M. 2005. Enterohaemorrhagic Esche-richia coli in human medicine. Int. J. Med. Microbiol. 295:405-418.
2. Orth D, Grif K, Khan AB, Naim A, Dierich MP, Würzner R. 2007. The Shiga toxin genotype rather than the amount of Shiga toxin or the cyto-toxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome. Diagn. Microbiol. Infect. Dis. 59:235-242.
3. Hurley BP, Jacewicz M, Thorpe CM, Lincicome LL, King AJ, Keusch GT, Acheson DW. 1999. Shiga toxins 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect. Immun. 67:6670-6677.
4. Betz J, Bielaszewska M, Thies A, Humpf HU, Dreisewerd K, Karch H, Kim KS, Friedrich AW, Müthing J. 2011. Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: differential association with membrane lipid raft microdomains. J. Lipid Res. 52: 618-634.
5. Betz J, Bauwens A, Kunsmann L, Bielaszewska M, Mormann M, Humpf HU, Karch H, Friedrich AW, Müthing J. 2012. Uncommon membrane distribution of Shiga toxin glycosphingolipid receptors in toxin-sensitive human glomerular microvascular endothelial cells. Biol. Chem. 393:133-147.
6. ObrigTG. 2011. Escherichia coli Shiga toxin mechanismsofaction in renal disease. Toxins (Basel) 2:2769-2794.
7. Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Würzner R. 2009. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J. Immunol. 182:6394-6400.
8. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H. 2009. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 4:1920-1924.
9. Ståhl AL, Sartz L, Karpman D. 2011. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Esche-richia coli-induced hemolytic uremic syndrome. Blood 117:5503-5513.
10. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F. 2011. Eculizumab in severe Shiga-toxin-associated HUS. N. Engl. J. Med. 364:2561-2563.
11. Orth-Höller D, Riedl M, Würzner R. 2011. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS-perfect example for a fast track from bench to bedside. EMBO Mol. Med. 3:617-619.
12. Muniesa M, Hammerl JA, Hertwig S, Appel B, Brussow H. 2012. Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl. Environ. Microbiol. 78:4065-4073.
13. Johnson S, Waters A. 2012. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 217:235-243.
14. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagen-muller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Munte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schocklmann H, Schreiber S, von Seydewitz CU, et al. 2012. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced hae-molytic uraemic syndrome: case-control study. BMJ 345:e4565. doi: 10.1136/bmj.e4565.
15. Zipfel PF, Skerka C. 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9:729-740.
16. Speth C, Würzner R, Stoiber H, Dierich MP. 2008. Complement, p 1047-1078. In Paul WE (ed), Fundamental immunology. Lippincott-Raven, Philadelphia, PA.
17. Hakulinen J, Junnikkala S, Sorsa T, Meri S. 2004. Complement inhibitor membrane cofactor protein (MCP; CD46)isconstitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur. J. Immunol. 34:2620-2629.
18. Seya T, Turner JR, Atkinson JP. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage ofC3b and C4b. J. Exp. Med. 163:837-855.
19. Liszewski MK, Post TW, Atkinson JP. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431-455.
20. Medof ME, Kinoshita T, Nussenzweig V. 1984. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 160:1558-1578.
21. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ. 1990. Human protectin (CD59), an18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1-9.
22. Nangaku M. 1998. Complement regulatory proteins in glomerular diseases. Kidney Int. 54:1419-1428.
23. Zhang W, Bielaszewska M, Pulz M, Becker K, Friedrich AW, Karch H, Kuczius T. 2008. New immuno-PCR assay for detection of low concentrations of Shiga toxin 2 and its variants. J. Clin. Microbiol. 46:1292-1297.
24. Satchell SC, Tasman CH, Singh A, Ni L, Geelen J, von Ruhland CJ, O'Hare MJ, Saleem MA, van den Heuvel LP, Mathieson PW. 2006. Conditionally immortalized human glomerular endothelial cells expressing fenestrations in response to VEGF. Kidney Int. 69:1633-1640.
25. Kinderlerer AR, Steinberg R, Johns M, Harten SK, Lidington EA, Haskard DO, Maxwell PH, Mason JC. 2006. Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. Arthritis Res. Ther. 8:R130. doi: 10.1186/ar2019.
26. Pattyn F, Speleman F, De Paepe A, Vandesompele J. 2003. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res. 31: 122-123.
27. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, Rottoli D, Tedesco F, Remuzzi G, Zoja C. 2011. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvas-cular thrombosis. J. Immunol. 187:172-180.
28. Quigg RJ, Holers VM, Morgan BP, Sneed AE, III. 1995. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J. Immunol. 154:3437-3443.
29. Quigg RJ, Morgan BP, Holers VM, Adler S, Sneed AE, III, Lo CF. 1995. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int. 48:412-421.
30. Hughes TR, Meri S, Davies M, Williams JD, Morgan BP. 1993. Immu-nolocalization and characterization of the rat analogue of human CD59 in kidney and glomerular cells. Immunology 80:439-444.
31. Rooney IA, Davies A, Griffiths D, Williams JD, Davies M, Meri S, Lachmann PJ, Morgan BP. 1991. The complement-inhibiting protein, protectin (CD59 antigen), ispresent and functionally activeonglomerular epithelial cells. Clin. Exp. Immunol. 83:251-256.
32. Matsuo S, Nishikage H, Yoshida F, Nomura A, Piddlesden SJ, Morgan BP. 1994. Role of CD59 in experimental glomerulonephritis in rats. Kidney Int. 46:191-200.
33. Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, Johnson RJ. 1997. A new model of renal microvascular endothelial injury. Kidney Int. 52:182-194.
34. van Bijnen ST, van Heerde WL, Muus P. 2012. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J. Thromb. Haemost. 10:1-10.
35. Qu Z, Liang X, Liu Y, Du J, Liu S, Sun W. 2009. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59. Mol. Immunol. 47:283-289.
36. Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G, Noris M. 2003. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum. Mol. Genet. 12:3385-3395.
37. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Muslumanoglu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH. 2003. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100:12966-12971.
38. Boyer O, Niaudet P. 2011. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int. J. Nephrol. 2011:908407. doi: 10.4061/2011/908407.
39. Cole DS, Hughes TR, Gasque P, Morgan BP. 2006. Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Mol. Immunol. 43:1953-1964.
40. Jones J, Morgan BP. 1995. Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology 86:651-660.
41. Pasch MC, Bos JD, Daha MR, Asghar SS. 1999. Transforming growth factor-beta isoforms regulate the surface expression of membrane cofac-tor protein (CD46) and CD59 on human keratinocytes. Eur. J. Immunol. 29:100-108.
42. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxinoneukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171:45-50.
43. Lingwood CA, Khine AA, Arab S. 1998. Globotriaosyl ceramide (Gb3) expression in human tumour cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to verotoxin. Acta Biochim. Pol. 45:351-359.
44. Khine AA, Firtel M, Lingwood CA. 1998. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J. Cell. Physiol. 176:281-292.
45. Petruzziello-Pellegrini TN, Yuen DA, Page AV, Patel S, Soltyk AM, Matouk CC, Wong DK, Turgeon PJ, Fish JE, Ho JJ, Steer BM, Khajoee V, Tigdi J, Lee WL, Motto DG, Advani A, Gilbert RE, Karumanchi SA, Robinson LA, Tarr PI, Liles WC, Brunton JL, Marsden PA. 2012. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndromeinhumans and mice. J. Clin. Invest. 122:759-776.
46. Boyd B, Lingwood C. 1989. Verotoxin receptor glycolipid in human renal tissue. Nephron 51:207-210.
47. Lingwood CA. 1994. Verotoxin-binding in human renal sections. Nephron 66:21-28.